AIM’s Latest Newsletter: The Research Edition, July 2023
Published:
08/01/2023

This month’s newsletter focuses on the latest news and scientific breakthroughs in melanoma research.
This edition features:
- Letter from AIM’s President, Sam Guild
- Notes From the Lab: Novel Targets for Immune Checkpoint Inhibitors
By Paul Bunk, Ph.D. candidate, Cold Springs Harbor Laboratory - In Plain English: Neoadjuvant Therapy for Melanoma, and How We Got Here
By Kim Margolin, M.D., FACP, FASCO - Clinical Trials Catch Up: An Interview with Joshua M.V. Mammen, M.D., Ph.D., F.A.C.S.
By Alicia Rowell, Vice President, AIM at Melanoma
Recent Posts

Oct. 14, 2025
The Power of Peer Support in Melanoma Survivorship

Oct. 07, 2025
I’ve Failed First-Line Therapy – Now What?

Sep. 09, 2025
Caring Through Loss: A Conversation on Bereavement

Sep. 05, 2025
Advocating for Patients: Letter to the FDA on RP1 Treatment Access

Sep. 04, 2025